Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971-982.
[2]
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-347.
[3]
Lundberg IE, Tjarnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955-1964.
[4]
Sontheimer RD. Dermatomyositis: an overview of current and emerging therapeutic options. Expert Opin Pharmacother. 2000;1(5):975-990.
[5]
Manger B, Rech J, Schmidt LE. Cutaneous manifestations of dermatomyositis. Clin Dermatol. 2018;36(5):609-616.
[6]
Spencer-Green G, Kim H, Werth VP. Management of dermatomyositis and anti-melanoma differentiation-associated gene 5 antibody. Curr Rheumatol Rep. 2019;21(11):61.
[7]
Kurtzman DJB, Wright NA, Lin J, et al. Management of dermatomyositis: current state of the art. J Am Acad Dermatol. 2016;74(3):355-368.
[8]
Tiniakou E, Mammen AL. Dermatomyositis and immune-mediated necrotizing myopathy: driving forces and therapeutic targets. Curr Opin Rheumatol. 2017;29(6):619-625.